US2816060A - Ferrous chelate compositions for oral administration - Google Patents

Ferrous chelate compositions for oral administration Download PDF

Info

Publication number
US2816060A
US2816060A US446416A US44641654A US2816060A US 2816060 A US2816060 A US 2816060A US 446416 A US446416 A US 446416A US 44641654 A US44641654 A US 44641654A US 2816060 A US2816060 A US 2816060A
Authority
US
United States
Prior art keywords
iron
oral administration
tablets
elemental
ferrous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US446416A
Inventor
Edgar B Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US446416A priority Critical patent/US2816060A/en
Application granted granted Critical
Publication of US2816060A publication Critical patent/US2816060A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S71/00—Chemistry: fertilizers
    • Y10S71/02—Chelating agent

Definitions

  • This invention relates to coiii" ositiohs useful for the oral administration of iron in therapeutic o'i' hylactic dosa e. More particularly it relates to compositi ns eontai'ning chelated iron in dial dosage u'nit form and to a method or compounding same.
  • I p I r The need for iron in the daily diet brine average individual is fully established and the conditions which result from a failure to supply the necessary minimum amount of iron per day are wen known. Iron deficiency or iron anemia is a condition which occurs in a large segment of the population, particularly in females.
  • Another object of the invention is to provide a convenient dosage unit form suitable for oral administration and capable of giving a high iron response.
  • favorable iron res onse is meant a significant increase in the hemoglobin count of a blood sample.
  • Other criteria are "also employed to show a favorable iron response and measured by any of these criteria the chelated iron composition of the present invention gives a highly favorable response.
  • chelated iron as the term is used herein it is desired 1 2,816,060 Patented Dec. 10, 1957 to include iron derivatives of compounds which fall within the scope of the formula wherein n is 2 to 6 inclusive, m is O'to 2 inclusive, D is CH COOH, --CH CH COOH or the alkali metal salts thereof (sodium, potassium and -NH.;), and A is the same as D, or lower alkyl or hydroxy lower alkyl.
  • carboxylic polyor diamino acids specifically included within ma nate formula may be mentioned ethylene a anine N,N' tetraacetic acid, propylene 1,2 -diamin N,N' tetraacetic acid, 1,3-diangii nopropanol-2-N,N' tetraace tic acid, diethylenetriamine N,N' tetraacetic acid, diethylenetriamine N,NN pentaacetic acid, hexamethylen'ediamine N,N' tetraacetic acid, [Hiydroxyethylethylenediarnine-N,N triacetic acid.
  • the solid pharmaceutical carrier to which the invention pertains may take the form of tablets; powders; capsules or other dosage forms which are particularly useful for oral ingestion.
  • Solid diluents and/or tablet adjuvants such as corn starch, lactose, t'alc, stcarieacid; magnesium stearate, gums and the like are all included in this class.
  • any of the tableting materials used in ordinary pharmaceutical practice may be employed where there is no incompatibility with the chelated iron of this invention.
  • the iron chelates used herein have between about 9% and 17% elemental iron and the bulk represented by the substantially inactive polycarboxylic amino acid residue may take the place of a diluent or filler in the oral dosage form.
  • the material may be tableted with or without adjuvants but it will ordinarily be better practice to employ at least the lubricating compounds such as talc, stearic acid and magnesium stearate.
  • the active material with or without its adjuvant materials may be placed in a capsule such as the usual gelatin capsule and administered in that form;
  • the active chelated iron com position may be put with or without adjuvants into powder packets or in powdered forth and administered in this manner.
  • the amount of chelated iron in the composition inthis' invention may be varied to suit certain individual situations. It is necessary, however, that the active ingredient constitute a proportion such that a suitable dosage will be obtained. It will be apparent that several unit dosage forms my be administered at the same time or in intervals. Hence, it will be apparent that any smallbut significant amount of chelated iron may be employed inacli dosage unit. As a practical matter i is desirable to have at least about 5 milligrams of ale tal iron present in each dosage unit and the amount iiiay be varied up: wardly from that point at will.
  • One particularly useful dosage unit which will be described in detail in the following examples contains siifiicient chelated iron to provide about 16% milligrams of elemental iron per tablet.
  • the patient may obtain 50 milligrams of elemental iron by taking one tablet three times 'a 'day. It has been found that this schedule of treatment will provide iron response comparable to that obtained with far greater amounts of elemental iron administered in the form of ferrous sulfateaccording to previously known practices.
  • Example I mental ferrous iron 120 Talc 6 Stearic acid 4 Magnesium stearate 2 Add 3 grams of talc and 2 grams of stearic acid to the sequestrene H Fe (Alrose Chemical Company) through a 40-mesh screen. Mix well and slug. Grind the slugs through a 4-mcsh screen and then through a 16-mesh screen. Add the remainder of lubricants through a 40- mesh screen and blend well. Compress on a convex punch so that 10 tablets weigh about 1.1 grams.
  • the tablets contain about 16 /3 milligrams of elemental ferrous iron per tablet and when taken three times daily to provide a daily dose of 50 milligrams of elemental iron the composition results in a high iron response as evidenced by a substantial increase in the hemoglobin count in the blood of patients taking the tablets.
  • the response is equal to or superior to that obtained when 200 milligrams per day of elemental iron is given in the form of ferrous sulfate.
  • the side reactions, vomiting and nausea, are far less in the composition of this invention.
  • Lactose, corn starch and other diluents or adjuvants may also be added if desired, and if added, they do not substantially alter the response obtained.
  • Example II 1200 tablets were made up according to the following directions:
  • Example I Grams Sequestrene H Fe (containing about 17% elemental ferrous iron) 60 Talc 3 Stearic acid 2 Magnesium stearate 1
  • the ingredients were compounded in the manner set forth in Example I and 10 such tablets weighed 0.55 gram.
  • the tablets were sub-coated with gelatin and acacia solution and sub-coating powder. Then a suitable syrup coating was applied and polished.
  • the tablets contained approximately 8 milligrams of elemental ferrous iron per tablet and three tablets per day were administered to provide a daily dose of 25 milligrams of elemental iron.
  • Favorable iron response was noted and there were no important side reactions.
  • Lactose, corn starch and other diluents and adjuvants may also be added if desired in order to make the tablet a desirable size and shape.
  • Example III 1500 tablets were made up according to the following directions:
  • the chelated iron' is passed through a 40-mesh screen and massed with the melted Carbowax. The mass is allowed to set for about 4 hours at about C. It is then granulated through a l6-mesh screen, talc, stearic acid, and magnesium stearate are added through a mesh screen and the composition is blended well. When compressed on an convex punch 10 such tablets weigh 2.2 grams.
  • These tablets contain about 16% milligrams of elemental ferrous iron per tablet.
  • Example IV A multiple viamin-mineral tablet was prepared according to the following directions:
  • Sequestrene H Fe (containing about 10% elemental Blend the chelated iron, sodium ascorbate, nicotinamide and pyridoxine hydrochloride and pass through a 40-mesh screen. Mass with 10% polyvinylpyrrolidone in anhydrous alcohol. Granulate through a 4-mesh screen and dry at F. for 18 hours. Pass the dried granulation through a 16-mesh screen and blend in the intrinsic factor concentrate, vitamin B powder, folic acid, thiamin mononitrate, riboflavin, calcium pantothenate, talc, stearic acid and pass through a 40-mesh screen into the main granulation. Mix well and compress on a /2 convex punch. 10 such tablets weighed 6.91 grams.
  • Tablets of this type are highly suitable for either therapeutic or prophylactic treatment of vitamin and iron deficiencies.
  • the tablets can be marketed uncoated, or they can be sugar coated or enteric coated as desired.
  • Example V 461 capsules were prepared according to the following directions:
  • Lactose 26 Pass the chelated iron and the lactose through a 40- mesh screen and encapsulate into gelatin capsules. Each capsule contains about 333- milligrams of elemental ferrous iron.
  • Example VI 2,000 tablets were prepared according to the following Charge the sequestrene iron and cane sugar into a mixer'and blend well. Prepare a hot starch paste, and
  • the theoretical iron content may vary between about 9% and 17% in different samples.
  • a solid composition for oral administration in dosage unit form for administering iron comprising at least about 5 mg. of a physiologically acceptable chelated ferrous iron in which the chelating compound is represented by the formula wherein n is 2 to 6 inclusive, m is to 2 inclusive, D is selected from the group consisting of -CH COOH, CH CH COOH, and the alkali metal salts thereof, A is selected from the group consisting of lower alkyl, hydroxy lower alkyl, CH COOH, CH CH COOH, and the alkalimetal salts thereof, and a non-toxic, solid pharmaceutical carrier.
  • a solid composition for oral administration for treatment of iron deficiencies comprising at least about 5 milligrams of elemental iron in the form of a ferrous salt of a chelating compound represented by the formula wherein n is 2 to 6 inclusive, m is 0 to 2 inclusive, D is selected from the group consisting of -CH COOH, CH CH COOH, and the alkali metal salts thereof, A is selected from the group consisting of lower alkyl, hydroxy lower alkyl, CH COOH, CH CH COOH, and the alkali metal salts thereof.
  • a solid composition for oral administration comprising a capsule of encapsulating material containing at least about 5 milligrams of elemental iron in the form of a ferrous salt of a chelating compound represented by the formula A A N(CH1),. N(CH:),. N D l l l.
  • n 2 to 6 inclusive
  • m 0 to 2 inclusive
  • D is selected from the group consisting of CH COOH, CH CH CO0H, and the alkali metal salts thereof
  • A is selected from the group consisting of lower alkyl, hydroxy lower alkyl, CH C0OH, CH CH COOH, and the alkali metal salts thereof.
  • a tablet for oral administration for the treatment of iron deficiencies containing a non-toxic, solid pharmaceutical carrier and at least about 5 milligrams of elemental iron in the form of a ferrous salt of a chelating compound represented by the formula N( 0 H2) -.[N( 0 a) ,.]N D 15 ZD wherein n is 2 to 6 inclusive, m is 0 to 2 inclusive, D is selected from the group consisting of CH COOH, -CH CH COOH, and the alkali metal salts thereof, A is selected from the group consisting of lower alkyl, hydroxy lower alkyl, -CH COOH, -CH CH COOH, and the alkali metal salts thereof.
  • a tablet for oral administration for therapeutic and prophylactic use containing a non-toxic, solid pharmaceutical carrier and at least about 5 milligrams of elemental iron in the form of a ferrous salt of ethylenediamine tetraacetic acid.
  • a solid composition for oral administration of iron which comprises at least about 5 milligrams of elemental iron in dosage unit form, said iron being in the form of the ferrous salt of ,B-hydroxyethylethylenediamine-N,N' triacetic acid- References Cited in the file of this patent FOREIGN PATENTS Germany Mar. 3, 1952 Great Britain June 24, 1940 OTHER REFERENCES 5th Ed., 1952,

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

Uni e tate Patifi 7 2,816,060 FERROUS CHELATECOMPOSITIONS For: ORAL ADMINISTRATION Edgar ll. Carter, j Iji'ghlaridPark, Ill., Aliliiitt Laboratories, Ehicagd, 111., a corporation of Illinois No Drawing. Application ill; h3 4, Serial No. 446,416
6 Claims. (Cl. 167-68) This invention relates to coiii" ositiohs useful for the oral administration of iron in therapeutic o'i' hylactic dosa e. More particularly it relates to compositi ns eontai'ning chelated iron in dial dosage u'nit form and to a method or compounding same. I p I r The need for iron in the daily diet brine average individual is fully established and the conditions which result from a failure to supply the necessary minimum amount of iron per day are wen known. Iron deficiency or iron anemia is a condition which occurs in a large segment of the population, particularly in females. The treatment of iron deficiency 53'' injections of i roi'l compounds and oral administration of iron is widespread butis attended With disadvantages to the patient. In oral administration of iron compounds for example, the, in ci'dence or nausea and other undesirable side reactions is quite prevalent. It has been necessary iii order to obtain favorable iron response in an iron deficient patient to'administ'e'r a comparatively large amount of iron per day to the adult patient. This large amount of iron; usually administered in the forrri of ferrous sulfate, often results in undesirable side reactions such as nausea and vomiting. In order to overcome this tendency it has become common practice to administer tablets containin'g only'a small portion of the total dosage at intervals and to thereby spread the total intake of iron over the full day. This in itself is inconvenient 'to the patient and does not always solve the problem of eliminating the undesirable side reactions.
It is an object of this invention to provide a composition which will give a high iron response in relatively small dosage and with a minimum of side effects.
Another object of the invention is to provide a convenient dosage unit form suitable for oral administration and capable of giving a high iron response.
In the accomplishment of the foregoing objects and in accordance with the practice of the present invention there is now provided a new iron composition useful for oral administration and containing as the active ingredient a chelated iron compound which may be associated with a solid pharmaceutical carrier. It was an unexpected finding of this invention that a highly favorable response could be obtained in humans using a relatively small dosage of a chelated iron composition because experiments in rats had proved unsatisfactory. It was found, for example, that a favorable ir'o'n response comparable to that obtained when ferrous sulfate is used as the'source of elemental iron could be obtained using only A to 73 the amount of elemental iron in the form of a chelated iron complex or co-o'rdina'tion compound. I
By favorable iron res onse is meant a significant increase in the hemoglobin count of a blood sample. Other criteria are "also employed to show a favorable iron response and measured by any of these criteria the chelated iron composition of the present invention gives a highly favorable response.
By chelated iron as the term is used herein it is desired 1 2,816,060 Patented Dec. 10, 1957 to include iron derivatives of compounds which fall within the scope of the formula wherein n is 2 to 6 inclusive, m is O'to 2 inclusive, D is CH COOH, --CH CH COOH or the alkali metal salts thereof (sodium, potassium and -NH.;), and A is the same as D, or lower alkyl or hydroxy lower alkyl. As examples of the carboxylic polyor diamino acids specifically included within ma nate formula may be mentioned ethylene a anine N,N' tetraacetic acid, propylene 1,2 -diamin N,N' tetraacetic acid, 1,3-diangii nopropanol-2-N,N' tetraace tic acid, diethylenetriamine N,N' tetraacetic acid, diethylenetriamine N,NN pentaacetic acid, hexamethylen'ediamine N,N' tetraacetic acid, [Hiydroxyethylethylenediarnine-N,N triacetic acid. Iron forms a stable complex orco-ordination compound with the above identified polycarboxylic amino acids and salts thereof and the iron is readily released from such co mpositions upon oral ingestion. The compounds referred to in this paragraph may also be conveniently named allrylenepolyamine polyacetic acids. V The solid pharmaceutical carrier to which the invention pertains may take the form of tablets; powders; capsules or other dosage forms which are particularly useful for oral ingestion. Solid diluents and/or tablet adjuvants such as corn starch, lactose, t'alc, stcarieacid; magnesium stearate, gums and the like are all included in this class. In fact, any of the tableting materials used in ordinary pharmaceutical practice may be employed where there is no incompatibility with the chelated iron of this invention. The iron chelates used herein have between about 9% and 17% elemental iron and the bulk represented by the substantially inactive polycarboxylic amino acid residue may take the place of a diluent or filler in the oral dosage form. The material may be tableted with or without adjuvants but it will ordinarily be better practice to employ at least the lubricating compounds such as talc, stearic acid and magnesium stearate. Alternatively the active material with or without its adjuvant materials may be placed in a capsule such as the usual gelatin capsule and administered in that form; Iii still another embodiment the active chelated iron com position may be put with or without adjuvants into powder packets or in powdered forth and administered in this manner.
The amount of chelated iron in the composition inthis' invention may be varied to suit certain individual situations. It is necessary, however, that the active ingredient constitute a proportion such that a suitable dosage will be obtained. It will be apparent that several unit dosage forms my be administered at the same time or in intervals. Hence, it will be apparent that any smallbut significant amount of chelated iron may be employed inacli dosage unit. As a practical matter i is desirable to have at least about 5 milligrams of ale tal iron present in each dosage unit and the amount iiiay be varied up: wardly from that point at will. One particularly useful dosage unit which will be described in detail in the following examples contains siifiicient chelated iron to provide about 16% milligrams of elemental iron per tablet. In this manner the patient may obtain 50 milligrams of elemental iron by taking one tablet three times 'a 'day. It has been found that this schedule of treatment will provide iron response comparable to that obtained with far greater amounts of elemental iron administered in the form of ferrous sulfateaccording to previously known practices.
. The followingex'ample's arepresehted in order to define the invention more clearly but it will be understood that the invention is not intended to be limited in any way' by these examples. '1 Example I mental ferrous iron) 120 Talc 6 Stearic acid 4 Magnesium stearate 2 Add 3 grams of talc and 2 grams of stearic acid to the sequestrene H Fe (Alrose Chemical Company) through a 40-mesh screen. Mix well and slug. Grind the slugs through a 4-mcsh screen and then through a 16-mesh screen. Add the remainder of lubricants through a 40- mesh screen and blend well. Compress on a convex punch so that 10 tablets weigh about 1.1 grams.
Add suflicient coats of cellulose acetate phthalate in solution, dusting with talc, until the tablets meet the U. S. P. disintegration test for enteric coatings. Sub-coat with gelatin and acacia and sub-coating powder. Apply syrup and polish.
The tablets contain about 16 /3 milligrams of elemental ferrous iron per tablet and when taken three times daily to provide a daily dose of 50 milligrams of elemental iron the composition results in a high iron response as evidenced by a substantial increase in the hemoglobin count in the blood of patients taking the tablets. The response is equal to or superior to that obtained when 200 milligrams per day of elemental iron is given in the form of ferrous sulfate. The side reactions, vomiting and nausea, are far less in the composition of this invention.
Lactose, corn starch and other diluents or adjuvants may also be added if desired, and if added, they do not substantially alter the response obtained.
Example II 1200 tablets were made up according to the following directions:
' Grams Sequestrene H Fe (containing about 17% elemental ferrous iron) 60 Talc 3 Stearic acid 2 Magnesium stearate 1 The ingredients were compounded in the manner set forth in Example I and 10 such tablets weighed 0.55 gram. The tablets were sub-coated with gelatin and acacia solution and sub-coating powder. Then a suitable syrup coating was applied and polished.
The tablets contained approximately 8 milligrams of elemental ferrous iron per tablet and three tablets per day were administered to provide a daily dose of 25 milligrams of elemental iron. Favorable iron response was noted and there were no important side reactions.
Lactose, corn starch and other diluents and adjuvants may also be added if desired in order to make the tablet a desirable size and shape.
Example III 1500 tablets were made up according to the following directions:
The chelated iron'is passed through a 40-mesh screen and massed with the melted Carbowax. The mass is allowed to set for about 4 hours at about C. It is then granulated through a l6-mesh screen, talc, stearic acid, and magnesium stearate are added through a mesh screen and the composition is blended well. When compressed on an convex punch 10 such tablets weigh 2.2 grams.
A special clear, colored enteric coating of cellulose acetate phthalate resin was applied to the tablets until they would meet the U. S. P. test for enten'c coating. It is not necessary to apply sub-coating and sugar-coating to these tablets since their appearance is highly satisfactory.
These tablets contain about 16% milligrams of elemental ferrous iron per tablet.
Example IV A multiple viamin-mineral tablet was prepared according to the following directions:
Sequestrene H Fe (containing about 10% elemental Blend the chelated iron, sodium ascorbate, nicotinamide and pyridoxine hydrochloride and pass through a 40-mesh screen. Mass with 10% polyvinylpyrrolidone in anhydrous alcohol. Granulate through a 4-mesh screen and dry at F. for 18 hours. Pass the dried granulation through a 16-mesh screen and blend in the intrinsic factor concentrate, vitamin B powder, folic acid, thiamin mononitrate, riboflavin, calcium pantothenate, talc, stearic acid and pass through a 40-mesh screen into the main granulation. Mix well and compress on a /2 convex punch. 10 such tablets weighed 6.91 grams.
Tablets of this type are highly suitable for either therapeutic or prophylactic treatment of vitamin and iron deficiencies. The tablets can be marketed uncoated, or they can be sugar coated or enteric coated as desired.
Example V 461 capsules were prepared according to the following directions:
Grams Sequestrene H Fe (containing 12% elemental ferrous iron) Lactose 26 Pass the chelated iron and the lactose through a 40- mesh screen and encapsulate into gelatin capsules. Each capsule contains about 333- milligrams of elemental ferrous iron.
Example VI 2,000 tablets were prepared according to the following Charge the sequestrene iron and cane sugar into a mixer'and blend well. Prepare a hot starch paste, and
Percent Ethylenediamine tetraacetic acid 72.1 Total iron 13.3 Ferrous iron 13.2 Theoretical iron content for trihydrate 13.9
The theoretical iron content may vary between about 9% and 17% in different samples.
Others may practice the invention in any of the numerous ways which will be suggested to one skilled in the art. It is contemplated that all such practices of the invention shall be covered hereby provided they fall within the scope of the appended claims.
I claim:
1. A solid composition for oral administration in dosage unit form for administering iron comprising at least about 5 mg. of a physiologically acceptable chelated ferrous iron in which the chelating compound is represented by the formula wherein n is 2 to 6 inclusive, m is to 2 inclusive, D is selected from the group consisting of -CH COOH, CH CH COOH, and the alkali metal salts thereof, A is selected from the group consisting of lower alkyl, hydroxy lower alkyl, CH COOH, CH CH COOH, and the alkalimetal salts thereof, and a non-toxic, solid pharmaceutical carrier.
2. A solid composition for oral administration for treatment of iron deficiencies comprising at least about 5 milligrams of elemental iron in the form of a ferrous salt of a chelating compound represented by the formula wherein n is 2 to 6 inclusive, m is 0 to 2 inclusive, D is selected from the group consisting of -CH COOH, CH CH COOH, and the alkali metal salts thereof, A is selected from the group consisting of lower alkyl, hydroxy lower alkyl, CH COOH, CH CH COOH, and the alkali metal salts thereof.
3. As a new article of manufacture a solid composition for oral administration comprising a capsule of encapsulating material containing at least about 5 milligrams of elemental iron in the form of a ferrous salt of a chelating compound represented by the formula A A N(CH1),. N(CH:),. N D l l l.
wherein n is 2 to 6 inclusive, m is 0 to 2 inclusive, D is selected from the group consisting of CH COOH, CH CH CO0H, and the alkali metal salts thereof, A is selected from the group consisting of lower alkyl, hydroxy lower alkyl, CH C0OH, CH CH COOH, and the alkali metal salts thereof.
4. A tablet for oral administration for the treatment of iron deficiencies containing a non-toxic, solid pharmaceutical carrier and at least about 5 milligrams of elemental iron in the form of a ferrous salt of a chelating compound represented by the formula N( 0 H2) -.[N( 0 a) ,.]N D 15 ZD wherein n is 2 to 6 inclusive, m is 0 to 2 inclusive, D is selected from the group consisting of CH COOH, -CH CH COOH, and the alkali metal salts thereof, A is selected from the group consisting of lower alkyl, hydroxy lower alkyl, -CH COOH, -CH CH COOH, and the alkali metal salts thereof.
5. A tablet for oral administration for therapeutic and prophylactic use containing a non-toxic, solid pharmaceutical carrier and at least about 5 milligrams of elemental iron in the form of a ferrous salt of ethylenediamine tetraacetic acid.
6. A solid composition for oral administration of iron which comprises at least about 5 milligrams of elemental iron in dosage unit form, said iron being in the form of the ferrous salt of ,B-hydroxyethylethylenediamine-N,N' triacetic acid- References Cited in the file of this patent FOREIGN PATENTS Germany Mar. 3, 1952 Great Britain June 24, 1940 OTHER REFERENCES 5th Ed., 1952,

Claims (1)

  1. 2. A SOLID COMPOSITION FOR ORAL ADMINISTRATION FOR TREATMENT OF IRON DEFICIENCIES COMPRISING AT LEAST 5 MILLIGRAMS OF ELEMENTAL IRON IN THE FORM OF A FERROUS SALT OF A CHELATING COMPOUND REPRESENTED BY THE FORMULA
US446416A 1954-07-28 1954-07-28 Ferrous chelate compositions for oral administration Expired - Lifetime US2816060A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US446416A US2816060A (en) 1954-07-28 1954-07-28 Ferrous chelate compositions for oral administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US446416A US2816060A (en) 1954-07-28 1954-07-28 Ferrous chelate compositions for oral administration

Publications (1)

Publication Number Publication Date
US2816060A true US2816060A (en) 1957-12-10

Family

ID=23772489

Family Applications (1)

Application Number Title Priority Date Filing Date
US446416A Expired - Lifetime US2816060A (en) 1954-07-28 1954-07-28 Ferrous chelate compositions for oral administration

Country Status (1)

Country Link
US (1) US2816060A (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2955981A (en) * 1957-12-31 1960-10-11 American Cyanamid Co Prevention of iron-deficiency anemias in suckling mammals
US2982690A (en) * 1958-05-26 1961-05-02 Diamond Lab Injectable veterinary iron compositions
US3027303A (en) * 1958-06-04 1962-03-27 Bristol Myers Co Hematinic compositions
US3033646A (en) * 1957-10-09 1962-05-08 Dow Chemical Co Method of separating rare earth metal ions
US3035978A (en) * 1957-08-12 1962-05-22 Ici Ltd Ferrocene hematinic compositions and therapy
US3088868A (en) * 1958-08-18 1963-05-07 Riker Laboratories Inc Orally-active therapeutic compositions and process for using same
US3091522A (en) * 1959-04-27 1963-05-28 Dow Chemical Co Method and composition for improving soil
US3107260A (en) * 1960-11-29 1963-10-15 Geigy Chem Corp Triaminopropane hexa-acetic acid and metal chelates thereof
US3115511A (en) * 1957-04-17 1963-12-24 Hampshire Chemical Corp Iron chelate compositions
US3139447A (en) * 1960-05-02 1964-06-30 Prod Chim Billault Fab Preparation of ferrous ferri-ethylenediamine-tetra-acetate and process
US3150160A (en) * 1960-10-17 1964-09-22 Geigy Chem Corp Metal salts and chelates of cyclohexyl or cyclopentyl triamino penta-achetic acids
US3151107A (en) * 1960-12-22 1964-09-29 Central Pharmacal Company Water-soluble iron complexes of carboxymethyl dextran
US3208995A (en) * 1961-06-22 1965-09-28 Cherokee Lab Inc Method of depolymerizing alginic acid salts and esters by reaction with no2
US3367834A (en) * 1965-05-04 1968-02-06 Dexter Martin Method and compositions for enhancing the utilization of iron by mammals
US5159094A (en) * 1991-05-15 1992-10-27 W.R. Grace & Co.-Conn. Process for the preparation of solid iron (III) complexes
US5274151A (en) * 1991-05-15 1993-12-28 Hampshire Chemical Corp. Process for the preparation of solid iron (III) complexes
US5446179A (en) * 1992-10-08 1995-08-29 Hampshire Chemical Corp. Process for the preparation of micronutrient blends
USRE37534E1 (en) * 1982-10-22 2002-01-29 Btg International Limited Pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB522646A (en) * 1937-12-20 1940-06-24 Ig Farbenindustrie Ag The manufacture of aqueous solutions having a high content of calcium
DE832889C (en) * 1950-03-06 1952-03-03 Cassella Farbwerke Mainkur Ag Process for the production of cobalt compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB522646A (en) * 1937-12-20 1940-06-24 Ig Farbenindustrie Ag The manufacture of aqueous solutions having a high content of calcium
DE832889C (en) * 1950-03-06 1952-03-03 Cassella Farbwerke Mainkur Ag Process for the production of cobalt compounds

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3115511A (en) * 1957-04-17 1963-12-24 Hampshire Chemical Corp Iron chelate compositions
US3035978A (en) * 1957-08-12 1962-05-22 Ici Ltd Ferrocene hematinic compositions and therapy
US3033646A (en) * 1957-10-09 1962-05-08 Dow Chemical Co Method of separating rare earth metal ions
US2955981A (en) * 1957-12-31 1960-10-11 American Cyanamid Co Prevention of iron-deficiency anemias in suckling mammals
US2982690A (en) * 1958-05-26 1961-05-02 Diamond Lab Injectable veterinary iron compositions
US3027303A (en) * 1958-06-04 1962-03-27 Bristol Myers Co Hematinic compositions
US3088868A (en) * 1958-08-18 1963-05-07 Riker Laboratories Inc Orally-active therapeutic compositions and process for using same
US3091522A (en) * 1959-04-27 1963-05-28 Dow Chemical Co Method and composition for improving soil
US3139447A (en) * 1960-05-02 1964-06-30 Prod Chim Billault Fab Preparation of ferrous ferri-ethylenediamine-tetra-acetate and process
US3150160A (en) * 1960-10-17 1964-09-22 Geigy Chem Corp Metal salts and chelates of cyclohexyl or cyclopentyl triamino penta-achetic acids
US3107260A (en) * 1960-11-29 1963-10-15 Geigy Chem Corp Triaminopropane hexa-acetic acid and metal chelates thereof
US3151107A (en) * 1960-12-22 1964-09-29 Central Pharmacal Company Water-soluble iron complexes of carboxymethyl dextran
US3208995A (en) * 1961-06-22 1965-09-28 Cherokee Lab Inc Method of depolymerizing alginic acid salts and esters by reaction with no2
US3367834A (en) * 1965-05-04 1968-02-06 Dexter Martin Method and compositions for enhancing the utilization of iron by mammals
USRE37534E1 (en) * 1982-10-22 2002-01-29 Btg International Limited Pharmaceutical compositions
US5159094A (en) * 1991-05-15 1992-10-27 W.R. Grace & Co.-Conn. Process for the preparation of solid iron (III) complexes
US5274151A (en) * 1991-05-15 1993-12-28 Hampshire Chemical Corp. Process for the preparation of solid iron (III) complexes
US5446179A (en) * 1992-10-08 1995-08-29 Hampshire Chemical Corp. Process for the preparation of micronutrient blends

Similar Documents

Publication Publication Date Title
US2816060A (en) Ferrous chelate compositions for oral administration
TWI410258B (en) Improved stability in vitamin and mineral supplements
UA29513C2 (en) PHARMACEUTICAL COMPOSITION, CONTAINING (E)-3,5-DIHYDROXY-7-[4¦-4"-FLUOROPHENYL-2'-CYCLOPRO PYL-QUINOLIN-3'-YL]-6-HEPTENOIC ACID</font>
GEP20043362B (en) Novel $G(Y)Crystalline Form of Perindopril Tert- Butylamine Salt, Preparation Method, and Pharmaceutical Compositions Containing Same
IL96699A (en) Formulations containing L-carnitine-L-tartrate
US3865935A (en) Tableting of erythromycin base
KR100263284B1 (en) More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent
GB1102934A (en) A process for the manufacture of benzdiaz[1,4]epine derivatives
IL99237A0 (en) Preparation of a tablet or dragee composition containing a moisture-,heat-and light-sensitive compound having monoclinic crystalline structure
SE509694C2 (en) Pharmaceutical compositions containing ranitidine / bismuth carboxylic acid salts
US4233317A (en) Analgesic potentiation
US4233314A (en) Analgesic potentiation
US3891755A (en) Dosage formulation for erythromycin cetyl sulfate
GB1487334A (en) Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof
US4206214A (en) Antithrombotic pharmaceutical compositions containing dipyridamole and sulfinpyrazone
US4447451A (en) Treatment of adult respiratory distress syndrome
US3005754A (en) Tetracycline formulations
EP0085544A1 (en) The use of aralkanoic acids and esters for the treatment of myelogenous leukemia
US3362879A (en) Tyrosine tranquilizing compositions and methods of treatment
US5153005A (en) Composition and method for preventing fluorosis
US3197370A (en) Pyrilamine tannate compositions
US4443476A (en) Treatment of adult respiratory distress syndrome
US3326760A (en) Choline salicylate polygalacturonate therapy
US3729563A (en) Method of treating movement disorders
US3806595A (en) Method of producing anorexia